MVA Vaccine Protects Mice from African Horse Sickness Virus
Author Information
Author(s): Castillo-Olivares Javier, Calvo-Pinilla Eva, Casanova Isabel, Bachanek-Bankowska Katarzyna, Chiam Rachael, Maan Sushila, Nieto Jose Maria, Ortego Javier, Mertens Peter Paul Clement
Primary Institution: Institute for Animal Health, Pirbright, Woking, Surrey, United Kingdom
Hypothesis
Can a modified vaccinia Ankara virus (MVA) vaccine expressing AHSV VP2 protect against AHSV challenge in an IFNAR −/− mouse model?
Conclusion
The MVA-VP2 vaccine provided complete protection against AHSV infection in the mouse model.
Supporting Evidence
- All vaccinated mice survived the challenge and showed no signs of viraemia.
- Unvaccinated control mice had a survival rate of only 50% and exhibited severe clinical signs.
- Statistical analysis indicated significant differences in survival rates between vaccinated and unvaccinated groups.
Takeaway
Researchers tested a vaccine on mice to see if it could protect them from a deadly horse virus, and it worked really well!
Methodology
The study involved infecting IFNAR −/− mice with AHSV-4 and evaluating the protective efficacy of the MVA-VP2 vaccine through clinical signs, survival rates, and virus titres.
Limitations
The study was conducted in a mouse model, which may not fully replicate the response in horses.
Participant Demographics
IFNAR −/− mice were used in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website